Research output per year
Research output per year
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation
Rodak, M., Dekempeneer, Y., Wojewodzka, M., Lahoutte, T., Bruchertseifer, F., Morgenstern, A., D'Huyvetter, M. & Pruszynski, M., 21 May 2021, Nuclear Medicine and Biology. Elsevier, Vol. 97-97. p. S33 1 p. SSP-30. (Nuclear Medicine and Biology; vol. 96-97, no. S33).Research output › peer-review
Open Access -
Targeted ALPHA therapy with single-domain antibody fragments, a novel cancer treatment
Dekempeneer, Y., Ooms, M. (Peer reviewer) & Cardinaels, T. (Peer reviewer), 2 Jun 2020, 218 p.Research output
-
Therapeutic Efficacy of 213 Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer
Dekempeneer, Y., Caveliers, V., Ooms, M., Gysemans, M., Lahoutte, T., Xavier, C., Lecocq, Q., Maes, K., Covens, P., Miller, B. W., Bruchertseifer, F., Morgenstern, A., Cardinaels, T. & D'huyvetter, M., 19 Jul 2020, In: Molecular Pharmaceutics. 17, 9, p. 3553-3566 14 p.Research output › peer-review
Open Access -
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior
Dekempeneer, Y., Bäck, T., Aneheim, E., Jensen, H., Puttemans, J. & Xavier, C., 21 Jun 2019, In: Molecular Pharmaceutics. 16, 8, p. 3524-3533 10 p.Research output › peer-review
Open Access